和铂医药（上海）有限公司 Harbour BioMed
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Nona Biosciences Appoints Dr. Hongjiang Miao as Chief AI Officer to Advance A³ Strategy and AI-Driven Drug Discovery 2025-12-04 10:01
Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology 2025-11-24 08:01
Nona Biosciences and Pfizer Announce Strategic Research Collaboration to Accelerate Antibody Discovery 2025-11-19 20:08
Harbour BioMed and Evinova China Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development 2025-11-07 14:00
Nona Biosciences Announces Expansion of Collaboration with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies 2025-11-05 20:07
Harbour BioMed Launches First Fully Human Generative AI HCAb Model to Accelerate Next-Generation Biologics Discovery 2025-10-28 22:07
Nona Biosciences Appoints Dr. Di Hong as Chief Executive Officer to Drive Technology Innovation and Strategic Growth 2025-10-15 08:00
Harbour BioMed Reports 2025 Interim Results 2025-08-27 22:40
Harbour BioMed Appoints Yajie Li as Chief Medical Officer 2025-08-25 09:00
Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025 2025-07-30 08:01
Harbour BioMed Announces Positive Profit Alert for 2025 Interim Results 2025-07-28 08:11
HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma 2025-07-23 20:36
Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers 2025-06-23 08:03
China National Intellectual Property Administration Affirms Validity of Harbour BioMed's Patent; Infringement Lawsuit Moves Forward 2025-06-16 20:33
Nona Biosciences and Visterra Partner to Advance Next-Generation Biotherapeutics for Immune-Mediated and Autoimmune Diseases 2025-06-12 20:03
Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting 2025-05-23 12:21
Nona Biosciences' Partner Pfizer Presents Preclinical Data on TOP1i-Based ADC Targeting MSLN at AACR Annual Meeting 2025 2025-04-28 08:00
Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer 2025-04-10 20:00
Harbour BioMed Appoints Youchen Chen as Chief Financial Officer 2025-04-10 10:00
Harbour BioMed Reports Full Year 2024 Financial Results 2025-03-31 18:13
1 2 3 4 5 7